MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Ahmet Zehir, Ryma Benayed, Ronak Shah et al. · Nature Medicine · 2017 · 3.5K citations

Medicine, Genetics, Oncology +16

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres, Alexander Drilon, Amélie Lusque et al. · Annals of Oncology · 2019 · 1.4K citations · Full text

Life Sciences, Immunology, Oncology +17

Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf, Takashi Seto, Ji‐Youn Han et al. · New England Journal of Medicine · 2020 · 997 citations · Full text

Medicine, Oncology, Pharmacology +15

The landscape of kinase fusions in cancer

Nicolas Stransky, Ethan Cerami, Stefanie S. Schalm et al. · Nature Communications · 2014 · 969 citations · Full text

Medicine, Cancer Biology, Oncology +17

<i>ALK</i> Rearrangements Are Mutually Exclusive with Mutations in <i>EGFR</i> or <i>KRAS</i>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

Justin F. Gainor, Anna M. Varghese, Sai‐Hong Ignatius Ou et al. · Clinical Cancer Research · 2013 · 608 citations · Full text

Medicine, Molecular Genetics, Oncology +14